ITUS (ANIX) Upgraded by Zacks Investment Research to Hold

Zacks Investment Research upgraded shares of ITUS (NYSE:ANIX) from a sell rating to a hold rating in a research note issued to investors on Monday morning, reports.

According to Zacks, “Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States. “

Shares of NYSE:ANIX opened at $4.50 on Monday. ITUS has a 12-month low of $2.96 and a 12-month high of $6.86.

In related news, Director Lewis H. Titterton, Jr. purchased 50,000 shares of the company’s stock in a transaction dated Monday, April 22nd. The shares were acquired at an average cost of $4.09 per share, with a total value of $204,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Arnold M. Baskies purchased 10,000 shares of the company’s stock in a transaction dated Friday, April 26th. The stock was bought at an average cost of $4.28 per share, for a total transaction of $42,800.00. The disclosure for this purchase can be found here. Insiders bought 74,900 shares of company stock worth $310,638 over the last ninety days.

ITUS Company Profile

Anixa Biosciences, Inc engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body’s immunological response to the presence of a malignancy.

See Also: Intrinsic Value

Get a free copy of the Zacks research report on ITUS (ANIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with's FREE daily email newsletter.